- PharMEdent 2019
- An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naïve chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution.
- Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Where to find us
NO.178, Shadab Cross, Sepahbod Gharani St., Tehran, Iran.
Our Office Hours
Sa-We: 8:00-14:00Sa: 8:00-14:00